Yüklüyor......
Randomized, controlled study of bleselumab (ASKP1240) pharmacokinetics and safety in patients with moderate‐to‐severe plaque psoriasis
This study evaluated the pharmacokinetics (PK), efficacy, safety, and tolerability of bleselumab – a fully‐human anti‐CD40 monoclonal recombinant IgG4. Patients with moderate‐to‐severe psoriasis were randomized on day 1 to receive bleselumab or placebo on days 1, 15 and 29 in a dose‐escalation of bl...
Kaydedildi:
| Yayımlandı: | Biopharm Drug Dispos |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6032846/ https://ncbi.nlm.nih.gov/pubmed/29679478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bdd.2130 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|